Chemotherapy alone versus combined modality therapy for Stage III Hodgkin’s disease: A five-year follow-up of a Southwest Oncology Group study (SWOG-7518) USA
- 43 Downloads
The relapse-free survival (RFS) rate for Stage III Hodgkin’s disease treated by conventional total nodal irradiation (TNI) alone (early 1970’s) was disappointingly low [1–4]. The development of successful combination chemotherapy by National Cancer Institute workers  led SWOG, in 1971, to devise a single arm study (SWOG-160, CAR-1) consisting of three MOPP cycles followed by TNI in Pathologic Stages IIB, IIIA, and IIIB Hodgkin’s disease. This trial, which was completed in 1975, achieved a complete response (CR) rate of 88% and an actuarial 5-year survival and RFS of 78% and 68% respectively . Improvement in survival and promising results obtained on another SWOG study with the addition of low dose bleomycin (LDB 2 mg/m2) to MOPP [7, 8] prompted SWOG to initiate, in October 1975, a randomized trial of chemotherapy (CT) alone compared to CT plus TNI for Stages IIIA and IIIB Hodgkin’s disease with LDB added to the CT regimen (SWOG-7518, CAR-2) [9, 10] (Fig. 1 and Table I).
KeywordsHerpes Zoster Southwest Oncology Group Combine Modality Therapy Nodular Sclerosis Southwest Oncology Group Study
Unable to display preview. Download preview PDF.
- 2.Goodman R, Rosenthal D, Botnick L et al. (1977). Stage IIIA Hodgkin’s disease: Results of treatment with total nodal irradiation. Proc Amer Assoc Cancer Res and Amer Soc Clin Oncol 18: 348.Google Scholar
- 6.Coltman CA Jr., Jones SE, Grozea PN et al. (1978). Bleomycin in combination with MOPP for the management of Hodgkin’s disease: Southwest Oncology Group Experience. In: Carter SK, Crooke ST and Umezawa H (Eds.). Bleomycin Current Status and New Developments, pp. 227–242. New York: Academic Press.Google Scholar
- 8.Coltman CA Jr, Montague E and Moon TE (1977). Chemotherapy and total nodal radiotherapy in pathological Stage IIB, IIIA and IIIB Hodgkin’s disease. In: Salmon SE and Jones SE (Eds.). Adjuvant Therapy of Cancer, pp. 529–536. Amsterdam, Oxford, New York: North-Holland, Publishing Company.Google Scholar
- 10.Grozea PN, DePersio EJ, Coltman CA Jr et al. (1982). A Southwest Oncology Group Study: Chemotherapy versus chemotherapy plus radiotherapy in the treatment of Stage III Hodgkin’s disease. In: Mathe G, Bonadonna G and Salmon S (Eds.). Recent Results in Cancer Research: Adjuvant Therapies of Cancer, pp. 83–91. Berlin, Heidelberg, New York: Springer-Verlag.Google Scholar
- 16.Coltman CA Jr, Myers JW, Montague E et al. (1982). The role of combined radiotherapy and chemotherapy in the primary management of Hodgkin’s disease: Southwest Oncology Group Studies. In: Rosenberg SA and Kaplan HS (Eds.). Malignant Lymphomas, Etiology, Immunology, Pathology, Treatment, pp. 523–536. New York: Academic Press.Google Scholar
- 17.Cooper D, Prosnitz LR, Kapp DS et al. (1984). Combined modality therapy for treatment of ‘poor-risk’ Stage IIIA Hodgkin’s disease. Proc Amer Soc Clin Oncol 3: 251.Google Scholar